Spike Protein News and Research

RSS

N439K mutation of SARS-CoV-2 may be more infectious and antibody resistant than Wuhan strain

Researchers from the Harbin Institute of Technology, China, modeled the complexes formed between the RBD and the human ACE2 and monoclonal antibodies.

27 Nov 2020

Siemens Healthineers SARS-CoV-2 IgG antibody test demonstrates ability to detect neutralizing antibodies

Siemens Healthineers has announced its SARS-CoV-2 IgG Antibody Test has proven to measure neutralizing antibodies and has achieved CE Mark. The test is an enhanced version of the assay which became available globally this summer.

From Siemens Healthineers 27 Nov 2020

Transgenic mouse model could recapitulate severe COVID-19 in humans

Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.

26 Nov 2020

Antihypertensive drugs may reduce COVID-19 mortality in at-risk patients

A new multicenter study that recently appeared on the medRxiv* preprint server in November 2020 has found a lower or equal risk of fatal COVID-19 in hypertensive patients, depending on the type of medication they are on.

26 Nov 2020

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

Specific SARS-CoV-2 genomic variations are associated with higher COVID-19 deaths

A team of scientists from South Korea and the United States has conducted an interesting study to investigate whether mutations in the genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can affect the severity of coronavirus disease 2019 (COVID-19). The study findings reveal that mutations in the viral spike protein and RNA polymerase complex can increase the risk of COVID-19 mortality.

25 Nov 2020

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the SARS-CoV-2 spike glycoprotein and, in turn, inhibit viral infection. Their findings are currently available on bioRxiv preprint server.

25 Nov 2020

Study: None of the SARS-CoV-2 mutations appear to increase transmissibility in humans

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

25 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Austrian study shows robust antibody response to SARS-CoV-2 for over 6 months

In the face of discouraging news about the resurgence of COVID-19, some reports offer hope of protection in the face of a robust and persistent immune response. In an encouraging report, an Austrian preprint appearing on the medRxiv server in November 2020 suggests a high level of durable immunity to SARS-CoV-2 over at least six months.

24 Nov 2020

Mefloquine shows potential as anti-SARS-CoV-2 drug

A team of scientists from Japan has identified the approved anti-material drug, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Specifically, mefloquine has been shown to prevent the entry of SARS-CoV-2 into host cells and reduce the viral load in vitro.

24 Nov 2020

Aprotinin inhibits SARS-CoV-2 entry and replication in cells cultures

Researchers at the University of Kent in the UK and the Hannover Medical School and Goethe University in Germany have observed that the protease inhibitor aprotinin can inhibit viral replication by preventing SARS-CoV-2 entry into host cells.

24 Nov 2020

Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.

From Avacta Life Sciences Ltd. 24 Nov 2020

Study: Aprotinin can inhibit virus replication by preventing SARS-CoV2 entry into host cells

The surface of the SARS-CoV-2 virus is studded with spike proteins. The virus needs these in order to dock onto proteins (ACE2 receptors) on the surface of the host cell.

24 Nov 2020

COVID-19: HLA class I genotypes and mortality

The study, published on the preprint server medRxiv, explores the ability of HLA class I molecules to mediate the outcome in COVID-19 patients.

24 Nov 2020

SARS-CoV-2's spike protein mutations have slowed, study finds

A team of researchers at the School of Information Sciences in Illinois, USA, has revealed the rate of mutation in the 29 proteins that make up the SARS-CoV-2 microbe.

23 Nov 2020

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Nasal dryness could be an early warning sign of COVID-19

A new study published by an international team of researchers on the preprint medRxiv* server in November 2020 details the nasal symptoms that are associated with anosmia and ageusia (loss of smell and taste) in coronavirus disease 2019 (COVID-19), including the early warning signs of infection.

23 Nov 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020

Compounds in traditional Chinese medicine herbs may inhibit SARS-CoV-2 infection

Using computational methods, a team of researchers identified three compounds in traditional Chinese medicine that could be used against SARS-CoV-2.

23 Nov 2020

Spike Protein News and Research

N439K mutation of SARS-CoV-2 may be more infectious and antibody resistant than Wuhan strain

Siemens Healthineers SARS-CoV-2 IgG antibody test demonstrates ability to detect neutralizing antibodies

Transgenic mouse model could recapitulate severe COVID-19 in humans

Antihypertensive drugs may reduce COVID-19 mortality in at-risk patients

Early interferon therapy may mitigate COVID-19 severity

Specific SARS-CoV-2 genomic variations are associated with higher COVID-19 deaths

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

Study: None of the SARS-CoV-2 mutations appear to increase transmissibility in humans

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Austrian study shows robust antibody response to SARS-CoV-2 for over 6 months

Mefloquine shows potential as anti-SARS-CoV-2 drug

Aprotinin inhibits SARS-CoV-2 entry and replication in cells cultures

Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test

Study: Aprotinin can inhibit virus replication by preventing SARS-CoV2 entry into host cells

COVID-19: HLA class I genotypes and mortality

SARS-CoV-2's spike protein mutations have slowed, study finds

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Nasal dryness could be an early warning sign of COVID-19

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

Compounds in traditional Chinese medicine herbs may inhibit SARS-CoV-2 infection

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News